// App-Quantinova.ai

337 : Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy: A “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy.

Researchers

Presenter

  • Maria Agnese Fabbri

Principal Investigators

  • Paolo Marchetti

  • Enrico Cortesi

  • Daniele Santini

  • Teresa Gamucci

  • Francesco Angelini

  • Isabella Sperduti

  • Flavia Longo

  • Arianna Pellegrino

  • Annalisa Milano

  • Silvia Quadrini

  • ML Mancini

  • Francesca Primi

  • Fabrizio Nelli

  • Raffaele Ratta

  • Enzo Ruggeri

Medical Centers

  • Division of Oncology, Ospedale Belcolle, Viterbo, Rome, Italy

  • Medical Oncology Unit Policlinico SantAndrea, Rome, Italy

  • Dipartimento di Oncologia Medica, Universita di Roma La Sapienza, Rome, Italy

  • Department of Anatomical Pathology, Campus Bio-Medico University of Rome, Rome, Italy

  • Medical Oncology Unit, Frosinone, Italy

  • Ospedale Regina Apostolorum, Roma, Italy

  • Bio-Statistics Unit Regina Elena National Cancer Institute, Italy, Rome, Italy

  • Policlinico Umberto I, Roma, Italy

  • Ospedale San Pietro Fatebenefratelli, Rome, Italy

  • AZ Ospedaliera S.Andrea, Rome, Italy

  • Policlinico Umberto I, Roma, Italy

  • Ospedale Belcolle, Viterbo, Italy

  • UO Oncologia, ASUL Viterbo, Viterbo, Italy

  • Unicampus University, Rome, Italy

  • Ospedale Belcolle, Viterbo, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Cabazitaxel

  • Prednisone

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved